Bexarotene benefits a subset of patients with NSCLC
Results of the SPIRIT II trial show that high-grade hypertriglyceridaemia in patients treated with bexarotene, as part of first-line therapy in patients with NSCLC, is correlated with increased survival....
Want to read complete article? Please Sign in or Register.